The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A.

DISCUSSION: Although rituximab is not a standard therapy for AHA, it may be useful in resistant cases. However, the definitive place of this monoclonal antibody in the therapeutic strategy for AHA (first or second-line, alone or in combination with other drugs) remains to be determined more precisely and warrants further investigation.
PMID: 26509821 [PubMed - as supplied by publisher]

Source: Blood Transfusion - September 3, 2015 Category: Hematology Authors: D'arena G, Grandone E, Di Minno MN, Musto P, Di Minno G Tags: Blood Transfus Source Type: research